Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome

Table 1 Main clinical, biochemical and histological data of the HIO patients (as a whole and according to gender) and HFE controls

				HIO
	HIO (n = 81)	P	HFE-HH (n = 57)	Men (n = 67)	P	Women (n = 14)
Age (yr)	52 (28-76)	> 0.05	50 (26-71)	54 (28-76)	> 0.05	51 (29-70)
Transferrin saturation (%)	39 (21-118)	< 0.0001	76 (29-100)	38 (21-118)	0.02	56 (28-99)
Serum ferritin (μg/L)	982 (413-5050)	> 0.05	1100 (274-10 990)	964 (413-5050)	> 0.05	1286 (520-3987)
AST (U/L)	27 (12-174)	> 0.05	27 (17-87)	27 (12-174)	> 0.05	28 (13-65)
ALT (U/L)	38 (11-271)	> 0.05	43 (11-114)	38 (14-271)	> 0.05	36 (11-118)
Total Iron Score	19 (12-46)	0.0071	24 (8-49)	18 (12-40)	0.0006	32 (12-46)
Hepatocytic iron score	15 (6-27)	0.001	18 (3-27)	12 (6-27)	0.0022	21 (9-27)
Sinusoidal iron score	5 (3-8)	< 0.0001	3 (0-10)	5 (3-7)	> 0.05	6 (3-8)
Portal iron score	0 (0-12)	0.0002	2 (0-12)	0 (0-8)	< 0.0001	3.5 (0-12)
SIS/TIS	0.25 (0.09-0.5)	< 0.0001	0.13 (0-0.63)	0.25 (0.10-0.5)	0.001	0.16 (0.09-0.29)
HHII	0.38 (0.20-1.21)	0.0012	0.53 (0.15-0.97)	0.36 (0.20-1.08)	0.004	0.64 (0.23-1.21)
Hepatic fibrosis (Ishak’s score)	34 (42)	> 0.05	33 (57.8)	26 (38.8)	> 0.05	8 (57.1)
Hepatic cirrhosis (Ishak’s score)	7 (8.6)	0.027	13 (22.8)	3 (4.5)	0.015	4 (28.6)
Patients with hepatic steatosis	47 (58)	0.015	20 (36.3)	41 (61.2)	> 0.05	6 (42.9)
Patients with moderate-severe hepatic steatosis	35 (43.2)	< 0.0001	6 (10.5)	31 (46.3)	> 0.05	4 (28.6)
Metabolic syndrome	20 (24.7)	> 0.05	91 (16.1)	19 (28.4)	> 0.05	1 (7.1)

Data are reported as median (range) or number (%). Hepatic steatosis: > 5% of hepatocytes involved by steatosis; Moderate-severe steatosis: ≥ 33% of hepatocytes involved by steatosis.

¹Not available in one HFE-control. SIS/TIS: Sinusoidal/total iron score; HHII: Histological hepatic iron index (ratio of TIS to age).